Cytokine Biomarkers as Indicators of Primary Graft Dysfunction, Acute Rejection, and Chronic Lung Allograft Dysfunction in Lung Transplant Recipients: A Review by Hallsten, John & Vigneswaran, Wickii T.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Cytokine Biomarkers as Indicators 
of Primary Graft Dysfunction, 
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Lung Allograft Dysfunction in 
Lung Transplant Recipients: A 
Review
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Abstract
Lung transplantation is well accepted form of treatment for end-stage lung 
disease in selected patients. The number of lung transplants performed worldwide 
has increased annually with chronic obstructive pulmonary disease being the lead-
ing cause. The morbidity and mortality in the early period are due to nonspecific 
primary graft dysfunction (PGD) and acute lung rejection (ALR). Chronic lung 
allograft dysfunction (CLAD) is the cause of long-term complications following 
lung transplantation and seen in almost half of the patient during the first 5 years. 
Activation of pro- and anti-inflammatory cytokines and chemokines has been 
described during various phases of lung transplantation recovery. We reviewed the 
literature for cytokine activity associated with PGD, ALR, and CLAD. This review 
aims to summarize the specific associations between bronchoalveolar lavage (BAL) 
and plasma cytokine levels and the association of PGD, ALR, and CLAD.
Keywords: cytokines, lung transplant, primary graft dysfunction, acute rejection, 
chronic lung allograft dysfunction
1. Introduction
The incidence of lung transplantations worldwide has increased annually with 
chronic obstructive pulmonary disease being the leading cause [1]. From 2009 to 
June 2016, the median survival of primary lung transplantation was 6.5 years [2]. 
The frequency of at least one treated acute rejection episode occurring within 1 year 
posttransplantation is around 27% [2]. Bronchiolitis obliterans syndrome (BOS), 
a phenotype of chronic lung rejection, is currently one of the most significant 
long-term complications of lung transplantation with a 5-year follow-up incidence 
of 41.5% [2].
Primary graft dysfunction (PGD) complicates lung transplant outcomes. PGD is 
a common early complication of lung transplantation that often occurs in the first 
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72 h posttransplantation [3]. PGD has also been indicated as a risk factor for the 
development of BOS [4].
Acute lung rejection (ALR) in lung transplant recipients is a major cause of early 
complication and death [5]. It is a major risk factor for the development of BOS 
[6]. BOS is the most common manifestation of chronic lung allograft dysfunction 
(CLAD) and is characterized by subepithelial fibrosis of small cartilaginous airways 
leading to partial or total occlusion [7].
PGD, ALR, and CLAD all have been associated with pro- and anti-inflammatory 
cytokine and chemokine expressions. This review aims to summarize the specific 
associations between bronchoalveolar lavage (BAL) and plasma cytokine levels and 
the development of PGD, ALR, and CLAD.
2. Methods
PubMed was explored using MeSH terms “lung transplantation,” “cytokines,” 
“biomarkers,” “acute rejection,” “chronic allograft dysfunction,” and “primary 
graft dysfunction.” Inclusion criteria consisted of studies through May 2018 
that provided information on plasma and/or BAL cytokines and acute rejection, 
chronic rejection, or primary graft dysfunction in lung transplant recipients. 
Prospective, retrospective, and review articles were included. The references 
of searched articles were also examined for potential studies to include. We 
focused on the following cytokines: interleukin (IL)-1a, IL-1b, IL-2, IL-4, IL-6, 
IL-8, IL-10, IL-12, IL-15, and IL-17; interferon-gamma (IFN-y); tumor necrosis 
factor-alpha (TNF-a); transforming growth factor-beta (TGF-b); and monocyte 
chemotactic protein (MCP)-1.
3. Primary graft dysfunction
PGD typically occurs within the first 72 h posttransplantation and is identified 
as ischemia-reperfusion injury with pulmonary edema that presents as increasing 
hypoxia in the affected patient [3].
Lung transplantation, and any other major surgeries, constitutes massive dam-
age to patient tissues.
TNF-α is one of the first cytokines to be released into circulation from such an 
injury, peaking in serum concentration around 1 h after the beginning of injury. 
IL-6, IL-8, and IL-10 are expressed and released in circulation shortly after, with 
peaks in concentration between 2 and 4 h after injury. Additionally, if injury sever-
ity increases, there is an associated shift away from a cell-mediated response to a 
humoral immune response [8].
Macrophage-associated cytokines IFN-y, TNF-a, and MCP-1 have all been 
strongly associated with PGD development in lung transplant recipients. Bharat 
and associates identified elevated serum IFN-γ in PGD positive patients [9]. Early 
release of TNF-α was associated with early hemodynamic failure posttransplanta-
tion [10]. In another study, elevated systemic TNF-α concentrations were associ-
ated with PGD development [11]. MCP-1, a macrophage chemotactic agent, has 
demonstrated a strong role in PGD. Shah and associates measured plasma MCP-1 at 
various time points in lung transplant recipients. They found elevated MCP-1 levels 
at 24 h posttransplantation were associated with PGD grade 3. These results attested 
to the importance of monocyte chemotaxis in PGD [12]. Another group of authors 
found similar results with elevated serum MCP-1 in PGD positive lung transplant 
recipients [13]. INF-γ is a potent activator of macrophages. Elevations in IFN-γ 
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along with increases in MCP-1, a strong monocyte chemotactic agent, suggest that 
ischemia-reperfusion injury increases macrophage activation.
Macrophage activation leads to release of pro-inflammatory cytokines, includ-
ing IL-6 and IL-8. PGD is linked to concomitant increases in IL-6 and IL-8 in 
lung transplant recipients. Early hemodynamic failure posttransplantation was 
associated with increases in both IL-6 and IL-8 [10]. A different study had similar 
results, in which IL-6 and IL-8 were both elevated in patients with PGD [11]. 
Moreno and associates found elevated BAL and blood IL-6 and IL-8 in patients 
with PGD. They are subsequently treated with inhaled nitric oxide, which lowered 
IL-6 and IL-8 and also decreased PGD incidence [14]. Increases in IL-6 often 
occur as a result of upstream macrophage-induced activation of Th1 immunity. In 
addition to macrophage activation, neutrophil chemotaxis from IL-8 upregulation 
is associated with increased PGD incidence. Increases in other pro-inflammatory 
cytokines caused by macrophage activation lead to pulmonary vasoconstriction 
and increased pulmonary vascular permeability, precipitating hemodynamic 
instability characteristic of PGD.
4. Acute lung rejection
In the weeks to months following transplantation, the allograft recipient’s 
T-cell-mediated immunity intensifies, potentially leading to the development of 
ALR. ALR is understood to be originally caused by mismatched MHC recognition 
and adaptive immune response [15].
Acute lung rejection is precipitated by the adaptive T-cell response. MHC mis-
match and the adaptive immune response are associated with T-cell activation and 
differentiation, which is facilitated by IL-2 [16]. It is expected that IL-2 would be 
increased in acute rejection; however the literature is conflicting on its association 
with lung rejection. Jordan and associates analyzed the serum of 17 lung transplant 
recipients and found serum IL-2 significantly elevated in patients with acute rejec-
tion confirmed; however, Moudgil and associates found no correlation between IL-2 
levels and acute rejection in lung transplant recipient [17, 18]. In addition to IL-2, 
IL-15 is a cytokine derived from stromal cells that behaves similarly to IL-2 in terms 
of biological function and is involved in T-cell chemoattraction to allografts [23]. 
Bhorade and associates measured IL-15 levels in BAL fluid of lung transplants and 
found that IL-15 was significantly elevated in patients experiencing acute rejection 
when the patients were given anti-CD25 monoclonal antibodies [19]. This study 
along with the evidence for IL-2 activation suggests the potential importance of 
IL-2 and IL-2 receptors in ALR immune responses.
T helper (Th) cells orchestrate the immune response and are divided into two 
subsets, Th1 and Th2 cells. T-cell differentiation into Th1 cells leads to increased 
expression of IFN-γ by Th1 cells. IFN-γ is involved in many important immune 
mechanisms and is a main component of the Th1 immune response, as it is a strong 
activator of macrophage-mediated antimicrobial and antitumor activity [20]. Its 
role in ALR is supported by a study measuring IFN-γ in BAL fluid of lung trans-
plantation patients, which found IFN-γ levels were significantly elevated in early 
acute rejection [18]. IL-12 is a known mediator of interferon-gamma expression 
[21]. D’ovidio and associates found IL-12 in BAL fluid elevated in acute rejec-
tion patients, which suggests it influences IFN-γ in ALR [22]. Ultimately, IFN-γ 
activation of macrophages induces pro-inflammatory cytokine release to cause 
inflammation.
IL-1, IL-6, and TNF-α are all acute phase pro-inflammatory cytokines that 
occur in most disease states and are secreted by activated macrophages to induce 
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inflammation. IL-1, which consists of both IL-1a and IL-1b, is a ubiquitous cyto-
plasmic cytokine that is associated with a plethora of disease states, including 
allograft rejection [23]. This family is associated with general acute phase reactions. 
Because the IL-1 family has been linked to several disease states, it is no surprise 
that lung transplant rejection bears an association to its expression. Specifically, 
Patella and associates recently found BAL IL-1β elevated in acute rejection episodes 
[24]. In another study, Rizzo and associates found significant increases in IL-1a and 
IL-1b expressions from alveolar macrophages of acute lung rejection patients com-
pared to patients without acute rejection [25]. IL-6 is another acute phase marker 
and pro-inflammatory cytokine that is involved in hematopoiesis and immune 
regulation [26]. Its role in immunity is similar to that of IL-1 cytokines, which 
leads it to also be elevated in acute rejection. The literature supports this claim. 
Whitehead and associates also found IL-6 significantly elevated in the BAL of acute 
lung rejection patients [27]. Patella and associates examined IL-6 in BAL samples 
of lung transplant recipients and found IL-6 to be higher in acute rejection cases 
[24]. The last of the acute phase cytokines is TNF-a. TNF-α has been associated with 
many disease processes, including infections, septic shock, and allograft rejection 
[28]. Hodge and associates found TNF-α was elevated in BAL CD4+ and CD8+ 
cells in acute lung rejection cases [29]. Magnan and associates measured TNF-α in 
alveolar macrophages and lung transplant recipients and found increased TNF-α in 
acute rejection [30].
In addition to acute phase cytokines, IL-8 is a known mediator of inflammation 
and neutrophil chemotaxis [31]. Its role in ALR, however, is minor. A recent study 
found no association between IL-8 and acute rejection [22].
Along with Th1, Th2 differentiation occurs with IL-2 activation of naive T 
cells. In addition, Th2 cell differentiation is activated by IL-4, a cytokine normally 
released by mast cells and basophils [32]. The literature is currently conflicting 
on the role of IL-4 in acute lung rejection. Whitehead and associates found BAL 
IL-4 elevated in acute lung rejection patients compared to patients without rejec-
tion [27]. On the other hand, another study looking at pro-inflammatory cytokine 
expression in lung transplant recipients found no difference in BAL, plasma, or 
bronchial brushing IL-4 levels between acute rejection and stable patients [29]. 
Based on conflicting literature, the Th2 response may not have a significant role in 
acute lung rejection.
The Th1 response is regulated by anti-inflammatory cytokines. IL-10 is an 
anti-inflammatory cytokine that is involved in immune response regulation 
and limiting of immune destruction to host tissues [33]. Patella and associates 
found that IL-10 was actually elevated in acute rejection cases compared to stable 
patients [24]. This evidence suggests IL-10 is elevated in an attempt to limit 
inflammation in ALR.
Monocyte and macrophage activity is strongly associated with activation of 
the Th1 response and is responsible for secretion of pro-inflammatory cytokines. 
IL-17, also known as IL-17A, is released by Th17 cells and induces monocytes and 
stromal cells to produce cytokines in addition to stimulating granulopoiesis. It is 
also involved in the pathogenesis of several autoimmune diseases [34]. In a study 
analyzed IL-17 mRNA and protein levels in BAL samples of lung transplant recipi-
ents, the authors found both IL-17 mRNA and protein levels significantly elevated 
in acute lung rejection [35]. MCP-1, also known as CCL-2, is a chemokine with 
strong mononuclear cell chemotaxis properties involved in chronic inflammation 
[36]. Belperio and associates evaluated BAL fluid from lung transplant recipients 
and found increased levels of MCP-1 in acute rejection cases compared to stable 
patients [37]. The role of MCP-1 and IL-17 suggest that mononuclear immune cell 
regulation occurs concomitantly to the Th1 response in ALR.
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5. Chronic lung allograft dysfunction
Airway inflammation is the main contributor to CLAD. CLAD encompasses 
many manifestations of chronic rejection, including BOS and RAS (restrictive 
allograft syndrome). Currently, it is characterized by a decrease in FEV1 and/or FVC 
by at least 20% compared to baseline, which is determined as a mean of two optimal 
postoperative measurements taken 3 weeks apart [38].
Pro-inflammatory cytokines IL-1, IL-6, and TNF-α are all upregulated in 
CLAD. Firstly, IL-1 has been studied in the setting of chronic rejection in lung 
transplantation. Suwara and associates studied cytokine expression in BAL fluid 
of lung transplant recipients with respect to different phenotypes of CLAD. They 
found IL-1a and IL-1b were elevated in lymphocytic bronchiolitis and persistent 
airway neutrophilia cases [39]. Verleden and associates also analyzed BAL fluid 
cytokines in different chronic lung rejection phenotypes and found IL-1b was 
significantly elevated in neutrophilic BOS and RAS episodes compared to stable 
patients [40]. In persistent airway neutrophilia, a specific phenotype of CLAD, 
BAL IL-6 was found to be significantly elevated [39]. Verleden and associates 
studied cytokine expression in BAL fluid of lung transplant recipients and found 
that IL-6 levels were elevated in RAS patient and correlated with survival among 
lung transplantation patients with RAS [40]. Lastly, TNF-α has been linked to 
CLAD. Suwara and associates studied cytokine expression in the context of several 
CLAD phenotypes. They found that BAL TNF-α levels were increased in patients 
with primary airway neutrophilia [39]. Additionally, Bharat and associates 
measured serum cytokines in patients with and without BOS after lung trans-
plantations. They found that IL-10 decreased threefold during the onset of BOS 
[41]. This evidence suggests that inflammation in the absence of regulation may 
contribute to airway inflammation in CLAD which likely arises from uninhibited 
pro-inflammatory cytokines.
Pro-inflammatory cytokine expression in CLAD may be a result of increased 
monocyte/macrophage chemotaxis. IFN-y, which activates macrophages to induce 
inflammation, has been indicated in chronic lung rejection. Hodge and associates 
found that, compared to BOS patients, stable lung transplant recipients displayed 
significant reductions in blood IFN-γ levels [42]. Both IL-17 and MCP-1, which are 
macrophage-recruiting cytokines, have been indicated in CLAD. MCP-1 was found 
elevated in patients before and during BOS indicating elevated MCP-1 posttrans-
plantation is predictive of BOS [13]. Fisichella and associates found increases in 
BAL IL-17 as an indicator of early onset BOS [43].
Unlike ALR, neutrophil-associated airway damage is strongly associated 
with CLAD development. IL-8 is known to facilitate neutrophil chemotaxis and 
has shown to be involved in chronic rejection among lung transplant recipients. 
DiGiovine and associates first established the contribution of IL-8 expression to 
airway neutrophilia and BOS development [44]. BAL IL-8 levels in lung trans-
plantation patients were elevated in neutrophilic BOS and RAS compared to stable 
patients in a recent study [40]. Elssner and associates found that IL-8 mRNA 
expression from bronchial cells was significantly elevated in BOS cases compared to 
stable patients [45].
The activity of IL-12 in CLAD is also contrary to ALR. IL-12 appears to attenu-
ate the development of CLAD, specifically BOS. Meloni and associates measured 
BAL cytokines in 44 lung transplant recipients and identified significant decreases 
in IL-12 to be correlative with BOS development [46]. Krenn and associates deter-
mined that azithromycin administration in lung transplant recipients reduced 
overall fibrosis and kept IL-12 levels from decreasing [47]. The authors remarked 
on the future significance of macrolide therapy in reduction of BOS development 
Perioperative Care for Organ Transplant Recipient
6
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Author details
John Hallsten and Wickii T. Vigneswaran*
Department of Thoracic and Cardiovascular Surgery, Loyola University Health 
System, Maywood, IL, USA
*Address all correspondence to: wickii.vigneswaran@lumc.edu
through effects on IL-12. The Th2 cytokine IL-4 has also shown to contribute to 
CLAD. Kastelijn and associates measured serum IL-4 levels in lung transplant 
recipients and found IL-4 levels were significantly lower in patients with BOS than 
BOS-negative patients [48]. The importance of IL-12 as a negative regulator as 
well as the potential role of IL-4 in CLAD indicates that the Th1 response may be 
downregulated in CLAD.
Chronic inflammation from persistent airway damage eventually leads to airway 
remodeling. TGF-β is an anti-inflammatory cytokine involved in tissue remodeling 
and scar formation [49]. Several studies have correlated TGF-β with the develop-
ment of chronic lung rejection episodes, including El-Gamel and associates who 
discovered elevated TGF-β levels in biopsies in patients with BOS [50]. Elssner 
and associates studied BAL fluid and respiratory epithelial lining fluid in lung 
transplant recipients and found that BOS patients had elevated TGF-β levels in both 
samples [45]. Another study correlated TGF-β levels with BOS, which validated 
the author’s claims that the biological role of TGF-β in tissue repair may also lead to 
airway fibrosis and obliteration [51].
6. Conclusions
The literature contains ample evidence on cytokines as biomarkers in lung trans-
plantation outcomes. PGD is augmented by IFN-y, IL-6, IL-8, TNF-a, and MCP-1. 
This could be explained by monocyte involvement and inflammatory changes dur-
ing ischemia-reperfusion injury. IL-1b, IL-6, IL-10, IL-15, and IFN-γ appear to be 
strong indicators to supplement the diagnosis of acute rejection in lung transplant 
recipients. These cytokines are linked to a Th1 immune response associated with 
acute inflammation. IL-1b, IL-6, IL8, IL-15, IL-17, IFN-γ, and TGF-β are significant 
contributors to chronic lung allograft dysfunction. IL-12 has also shown to attenu-
ate chronic lung rejection. CLAD appears to be more associated with inflammation 
and airway neutrophil chemotaxis.
The role of cytokines requires more controlled studies in order for diagnostic 
characteristics to be attributed. That being said, cytokines and chemokines in 
primary graft dysfunction, acute rejection, and chronic allograft dysfunction are 
promising markers of future diagnostic tests and targets of therapies to ultimately 
improve outcomes and survival in lung transplant recipients.
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